Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here [Benzinga]
Friday, September 22, 2023 1 min read
Key Takeaway: Enveric Biosciences has been granted a new patent by the U.S. Patent and Trademark Office for its psilocybin-based molecules, specifically the EVM301 series. This patent includes rights to the novel composition of matter and methods of use, potentially strengthening the company's position in the biopharma sector.
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences has secured a U.S. patent for innovative psilocybin derivatives.
The patent covers both the composition of matter and methods of use.
This development may enhance the company's intellectual property portfolio.
Full Press Release Details
The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its developer, Enveric Biosciences.
Full Story
Frequently Asked Questions
What patent did Enveric Biosciences receive?
Enveric Biosciences received a U.S. patent for novel psilocybin-based molecules.
What does the patent cover?
The patent covers the composition of matter and methods of use for EVM301.
Who granted the patent to Enveric?
The U.S. Patent and Trademark Office granted the patent to Enveric Biosciences.
What is the significance of this patent?
This patent strengthens Enveric's intellectual property portfolio in the biopharma sector.